Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Enterprise Value (2023 - 2025)

Kura Oncology (KURA) has disclosed Enterprise Value for 3 consecutive years, with -$667.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 8.27% to -$667.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$667.2 million, a 8.27% increase, with the full-year FY2025 number at -$667.2 million, up 8.27% from a year prior.
  • Enterprise Value was -$667.2 million for Q4 2025 at Kura Oncology, down from -$549.7 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$405.9 million in Q1 2023 to a low of -$727.4 million in Q4 2024.
  • A 3-year average of -$538.9 million and a median of -$509.3 million in 2024 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 71.57% in 2024, then grew 8.27% in 2025.
  • Kura Oncology's Enterprise Value stood at -$424.0 million in 2023, then crashed by 71.57% to -$727.4 million in 2024, then rose by 8.27% to -$667.2 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Enterprise Value are -$667.2 million (Q4 2025), -$549.7 million (Q3 2025), and -$630.7 million (Q2 2025).